 Shares of Aptinyx Inc. APTX, -4.49 tumbled 48.7 in premarket trading on Thursday after the company said an experimental treatment for painful diabetic peripheral neuropathy failed to meet the primary endpoint in a Phase 2b clinical trial. The data from this study do not currently point to a path forward in development for painful DPN, Aptinyx CEO Andy Kidd said in a news release. 